Using anticholinergics to treat overactive bladder: The issue of treatment tolerability

American Journal of Medicine

Volumn 119, Issue 3 SUPPL. 1, 2006, Pages 9-15

  Staskin, David R ^a,c   MacDiarmid, Scott A ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c F 918 ^*  (United States)

Author keywords

Anticholinergics; Bladder detrusor muscle; Extended release oxybutynin; Muscarinic receptor subtypes; Overactive bladder

Indexed keywords

ACETYLCHOLINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; OXYBUTYNIN; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

ABDOMINAL PAIN; ANTICHOLINERGIC SYNDROME; ANXIETY DISORDER; APPLICATION SITE REACTION; ASTHENIA; BLOOD PRESSURE FLUCTUATION; BLURRED VISION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; CYSTITIS; DEPRESSION; DETRUSOR MUSCLE; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; DYSPHAGIA; EDEMA; ERYTHEMA; GASTRITIS; HEADACHE; HUMAN; INSOMNIA; INTESTINE OBSTRUCTION; LETHARGY; MICTURITION DISORDER; MUSCLE HYPERTONIA; MUSCLE SPASM; NAUSEA; NERVOUSNESS; NONHUMAN; OVERACTIVE BLADDER; PAIN; PHYSICIAN; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; SOMNOLENCE; SUBDURAL HEMATOMA; TREATMENT WITHDRAWAL; TREMOR; URINARY TRACT INFECTION; VERTIGO; VISUAL DISORDER; XEROSTOMIA;

EID: 32444441009     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.12.011     Document Type: Article

References (28)

1. P. Abrams, L. Cardozo, M. Fall Standardisation Sub-committee of the International Continence Society The standardisation of terminology of lower urinary tract function report from the Standardisation Sub-committee of the International Continence Society Neurourol Urodyn 21 2002 167 178
2. K.S. Coyne, Z. Zhou, C. Thompson, E. Versi The impact on health-related quality of life of stress, urge, and mixed urinary incontinence BJU Int 92 2003 731 735
3. J.G. Ouslander Management of overactive bladder N Engl J Med 350 2004 786 799
4. J.N. Liberman, T.L. Hunt, W.F. Stewart Health-related quality of life among adults with symptoms of overactive bladder results from a U.S. community-based survey Urology 57 2001 1044 1050
5. K.E. Andersson Antimuscarinics for treatment of overactive bladder Lancet Neurol 3 2004 46 53
6. R.A. Appell The newer antimuscarinic drugs bladder control with less dry mouth Cleve Clin J Med 69 2002 761 765-766, 768-769
7. R.U. Anderson, D. Mobley, B. Blank, D. Saltzstein, J. Susset, J.S. Brown OROS Oxybutynin Study Group Once daily controlled versus immediate release oxybutynin chloride for urge incontinence J Urol 161 1999 1809 1812
8. P. Van Kerrebroeck, K. Kreder, U. Jonas, N. Zinner, A. Wein Tolterodine Study Group Tolterodine once-daily superior efficacy and tolerability in the treatment of the overactive bladder Urology 57 2001 414 421
9. R.R. Dmochowski, P.K. Sand, N.R. Zinner, M.C. Gittelman, G.W. Davila, S.W. Sanders Transdermal Oxybutynin Study Group Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence Urology 62 2003 237 242
10. E. Versi, R. Appell, D. Mobley, W. Patton, D. Saltzstein Ditropan XL Study Group Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence Obstet Gynecol 95 2000 718 721
11. D.M. Gleason, J. Susset, C. White, D.R. Munoz, P.K. Sand Ditropan XL Study Group Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence Urology 54 1999 420 423
12. S.A. MacDiarmid, R.U. Anderson, R.B. Armstrong, R.R. Dmochowski Efficacy and safety of extended-release oxybutynin for the treatment of urge incontinence an analysis of data from three flexible-dosing studies J Urol 174 2005 1301 1305
13. H.M. Scarpero, R.R. Dmochowski Muscarinic receptors what we know Curr Urol Rep 4 2003 421 428
14. M.P. Caulfield, N.J. Birdsall International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors Pharmacol Rev 50 1998 279 290
15. T. Yamanishi, C.R. Chapple, R. Chess-Williams Which muscarinic receptor is important in the bladder? World J Urol 19 2001 299 306
16. C. Chapple, W. Steers, P. Norton A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder BJU Int 95 2005 993 1001
17. R. Millard, J. Tuttle, K. Moore Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity J Urol 161 1999 1551 1555
18. S.A. MacDiarmid Overactive bladder improving the efficacy of anticholinergics by dose escalation Curr Urol Rep 4 2003 446 451
19. R.A. Appell, P. Sand, R. Dmochowski Overactive Bladder: Judging Effective Control and Treatment Study Group Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder results of the OBJECT study Mayo Clin Proc 76 2001 358 363
20. D.R. Staskin, S.A. MacDiarmid Pharmacologic management of overactive bladder practical options for the primary care physician Am J Med 119 suppl 3A 2006 24S 28S
21. A.C. Diokno, R.A. Appell, P.K. Sand OPERA Study Group Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder results of the OPERA trial Mayo Clin Proc 78 2003 687 695
22. F.M. Chu, R.R. Dmochowski, D.J. Lama, R.U. Anderson, P.K. Sand Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles a subanalysis of data from the OPERA trial Am J Obstet Gynecol 192 2005 1849 1854 discussion 1854-1855
23. N. Zinner, M. Gittelman, R. Harris, J. Susset, A. Kanelos, S. Auerbach Trospium Study Group Trospium chloride improves overactive bladder symptoms a multicenter phase III trial J Urol 171 2004 2311 2315
24. K. Ikeda, S. Kobayashi, M. Suzuki M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland Naunyn Schmiedebergs Arch Pharmacol 366 2002 97 103
25. C.R. Chapple, P. Arano, J.L. Bosch, D. De Ridder, A.E. Kramer, A.M. Ridder Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study BJU Int 93 2004 71 77
26. C.R. Chapple, T. Rechberger, S. Al-Shukri YM-905 Study Group Randomized, double-blind placebo-and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder BJU Int 93 2004 303 310
27. L. Cardozo, M. Lisec, R. Millard Randomized, double-blind placebo-controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder J Urol 172 2004 1919 1924
28. 3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder Eur Urol 45 2004 420 429